Translational Oncology involves moving scientific discoveries made in a laboratory setting into clinical applications that enhance treatment efficacy and outcomes for cancer patients. Translational Oncology approaches include pre-clinical research, which can be done in an in vivo, in vitro, or ex vivo setting, before validating the laboratory findings with a clinical trial.
DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
DATE: November 13, 2019TIME: 12:00pm PT NK cells play a major role in immune surveillance and in the early immune response to cancer and infections. Beneficial anti-tumor respo...
DATE: October 29, 2019TIME: 8:00am PDTAlthough immune-based therapies targeting the inhibitory receptors (PD-L1, PD1, and CTLA4) are proven to be effective to treat cancer, some pati...
Metastatic castration resistant prostate cancer (mCRPC) refractory to secondary hormonal treatments such as enzalutamide or abiraterone acetate are the most lethal of prostate cancers. In thi...
Osteosarcoma (OS) is the most common bone tumor in pediatric and adolescent/young adult patients. Over the past three decades, significant improvements in the survival rates or therapeutic ap...
Although about one in every seven men in the developed world will be diagnosed with prostate cancer in their lifetime, the mortality rate remains low with a 99% five-year survival rate for lo...
DATE: September 17, 2019TIME: 9:00am PTSpatial Transcriptomics (ST) technology reveals gene expression from up to one thousand spots across a tissue section. In this webinar, Dr. H...
DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
DATE: August 15, 2019TIME: 9:00am PDT, 12:00pm EDT Radiation therapy is a critical tool for the treatment of brain tumors, however, exposure to high doses of ionizing radiation...
The practice of precision medicine utilizes advanced diagnostic tools to identify specific groups of patients on the basis of particular molecular characteristics, and guide their treatment w...
Tumor heterogeneity is a hallmark of cancer and can have significant impact on identifying drivers, including those that may be therapeutically relevant. Although, the traditional sequencing...
This talk will review successful efforts at Washington University to employ novel reagents and informatics to the problem of rare allele detection. I will discuss a published bakeoff of in si...
The development of automated DNA sequencers utilizing Sanger sequencing and capillary electrophoresis made it possible to develop the first draft sequences of the human genome. The cost of do...
In this presentation, Dr. Kothari will provide an overview of the Precision Medicine Initiative from NIH and how NGS technologies have helped the researchers to look deep inside the human tra...
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
The NIH put Precision Medicine on the map as a revolutionary way to manage disease, delivering the right treatment, to the right patient, at the right time. But what does Precision Medicine r...
DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
Integration of technology is influencing practice in the clinical laboratory and treatment of patients in the clinical practice arena. As laboratories begin to move from a volume to value mod...
Personalized medicine driven by genomic-based treatments continues to increase in importance. Representatives from two distinct healthcare entities – a regional reference lab and commun...
Determining which patients would derive clinical benefit from immunotherapy is a compelling clinical question. Biomarkers have been shown to predict therapy outcome in various types of cancer...
Dramatic responses observed with targeted agents in the ‘right’ genomic context have fueled large scale sequencing efforts to identify ‘effective’ treatments for a giv...
NTRK fusions are rare but important recent biomarkers linked to response to new TRK inhibitors. Comprehensive genomic profiling on all solid tumors permits detection of rare genomic events an...
DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
DATE: November 13, 2019TIME: 12:00pm PT NK cells play a major role in immune surveillance and in the early immune response to cancer and infections. Beneficial anti-tumor respo...
DATE: October 29, 2019TIME: 8:00am PDTAlthough immune-based therapies targeting the inhibitory receptors (PD-L1, PD1, and CTLA4) are proven to be effective to treat cancer, some pati...
Metastatic castration resistant prostate cancer (mCRPC) refractory to secondary hormonal treatments such as enzalutamide or abiraterone acetate are the most lethal of prostate cancers. In thi...
Osteosarcoma (OS) is the most common bone tumor in pediatric and adolescent/young adult patients. Over the past three decades, significant improvements in the survival rates or therapeutic ap...
Although about one in every seven men in the developed world will be diagnosed with prostate cancer in their lifetime, the mortality rate remains low with a 99% five-year survival rate for lo...
DATE: September 17, 2019TIME: 9:00am PTSpatial Transcriptomics (ST) technology reveals gene expression from up to one thousand spots across a tissue section. In this webinar, Dr. H...
DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
DATE: August 15, 2019TIME: 9:00am PDT, 12:00pm EDT Radiation therapy is a critical tool for the treatment of brain tumors, however, exposure to high doses of ionizing radiation...
The practice of precision medicine utilizes advanced diagnostic tools to identify specific groups of patients on the basis of particular molecular characteristics, and guide their treatment w...
Tumor heterogeneity is a hallmark of cancer and can have significant impact on identifying drivers, including those that may be therapeutically relevant. Although, the traditional sequencing...
This talk will review successful efforts at Washington University to employ novel reagents and informatics to the problem of rare allele detection. I will discuss a published bakeoff of in si...
The development of automated DNA sequencers utilizing Sanger sequencing and capillary electrophoresis made it possible to develop the first draft sequences of the human genome. The cost of do...
In this presentation, Dr. Kothari will provide an overview of the Precision Medicine Initiative from NIH and how NGS technologies have helped the researchers to look deep inside the human tra...
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
The NIH put Precision Medicine on the map as a revolutionary way to manage disease, delivering the right treatment, to the right patient, at the right time. But what does Precision Medicine r...
DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
Integration of technology is influencing practice in the clinical laboratory and treatment of patients in the clinical practice arena. As laboratories begin to move from a volume to value mod...
Personalized medicine driven by genomic-based treatments continues to increase in importance. Representatives from two distinct healthcare entities – a regional reference lab and commun...
Determining which patients would derive clinical benefit from immunotherapy is a compelling clinical question. Biomarkers have been shown to predict therapy outcome in various types of cancer...
Dramatic responses observed with targeted agents in the ‘right’ genomic context have fueled large scale sequencing efforts to identify ‘effective’ treatments for a giv...
NTRK fusions are rare but important recent biomarkers linked to response to new TRK inhibitors. Comprehensive genomic profiling on all solid tumors permits detection of rare genomic events an...
Opens in a new windowOpens an external siteOpens an external site in a new window